VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production

Pancreas

Volumn 30, Issue 1, 2005, Pages 62-70

  Kojima, Mizuho ^a   Ito, Tetsuhide ^a,b   Oono, Takamasa ^a   Hisano, Terumasa ^a   Igarashi, Hisato ^a,b   Arita, Yoshiyuki ^a   Kawabe, Ken ^a   Coy, David H ^c   Jensen, Robert T ^b   Nawata, Hajime ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Acute pancreatitis; Cytokine; Monocyte; Vasoactive intestinal peptide; VPAC receptor

Indexed keywords

AMYLASE; CERULETIDE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SECRETIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE 1 AGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE 2 AGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; ENZYME INHIBITION; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLEEN;

ACUTE DISEASE; AMYLASES; ANIMALS; CAERULEIN; CYTOKINES; INTERLEUKIN-10; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MONOCYTES; PANCREAS; PANCREATITIS; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SPLEEN; TUMOR NECROSIS FACTOR-ALPHA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 19944429783     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Honda H, Nakamura H, Otsuki M. The elongated PAP II/Reg III mRNA is upregulated in rat pancreas during acute experimental pancreatitis. Pancreas. 2002;25:192-197.
2. + T cells play an important role in acute experimental pancreatitis in mice. Gastroenterology. 2000;118:582-590.
3. Norman JG. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg. 1998;175:76-83.
4. Osman MO, Gesser B, Mortensen JT, et al. Profiles of pro-inflammatory cytokines in the serum of rabbits after experimentally induced acute pancreatitis. Cytokine. 2002;17:53-59.
5. Said SI, Mutt V Potent peripheral splanchnic vasodilator peptide from normal gut. Nature. 1970;225:863-864.
6. Said SI, Mutt V Polypeptide with broad biological activity: isolation from small intestine. Science. 1970;169:1217-1218.
7. Dockray GJ. Vasoactive intestinal polypeptide and related peptides. In: Walsh JH, Dockray GJ, eds. Gut Peptides. New York: Raven; 1994:447-472.
8. Muller JM, Lelievre V, Becq-Giraudo L, et al. VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. Mol Neurobiol. 1995;10:115-134.
9. Jiang S, Kopras E, McMicheal M, et al. Vasoactive intestinal polypeptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res. 1997;57:1475-1480.
10. Moody TW, Leyton J, Gozes I, et al. VIP and breast cancer. Ann N Y Acad Sci. 1998;865:290-296.
11. Gozes I, Brenneman DE. A new concept in the pharmacology of neuroprotection. J Mol Neurosci. 2000;14:61-68.
12. Jensen SL, Fahrenkrug J, Holst JJ, et al. Secretary effects of VIP on isolated perfused pancreas. Am J Physiol. 1978;235:E387-E391.
13. Couvineau A, Rouyer-Fessard C, Darmoul D, et al. Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun. 1994;200:769-776.
14. Ulrich CD, Holtmann M, Miller LJ. Secretin and Vasoactive intestinal polypeptide receptor: members of a unique family of G protein-coupled receptors. Gastroenterology. 1998;114:382-397.
15. Reubi JC, Laemmli UK, Wase B, et al. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 2000;60:3105-3112.
16. 2 receptors, which mediate enzyme secretion. Am J Physiol Gastrointest Liver Physiol. 2000;278:G64-G74.
17. Ito T, Igarashi H, Pradhan TK, et al. GI side-effects of a possible therapeutic GRF analogue in monkey are likely due to VIP receptor agonist activity. Peptides. 2001;22:1139-1151.
18. 1 Receptors in human, rat, and guinea pig. J Pharmacol Ther. 2002;301:37-50.
19. Delgado M, Munoz-Elias EJ, Gomariz RP, et al. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J Neuroimmunol. 1999;96:167-181.
20. Johnson MC, McCormack RJ, Delgado M, et al. Murine T-lymphocytes express vasoactive intestinal peptide receptor type 1 (VIP-R1) mRNA. J Neuroimmunol. 1996;68:109-119.
21. Dewit D, Goulet P, Amraoui Z, et al. The vasoactive intestinal peptide analogue RO25-1553 inhibits the production of TNF and IL-12 by LPS-activated monocytes. Immunol Lett. 1998;118:57-60.
22. Martinez C, Delgado M, Pozo D, et al. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol. 1998;85:155-167.
23. Lara-Marquez ML, O'Dorisio MS, O'Dorisio TM, et al. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol. 2001;166:2522-2530.
24. Delgado M, Gomariz RP, Martinez C, et al. Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol. 2000;30:3236-3246.
25. Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and 1L-6. J Immunol. 1999;162:1200-1205.
26. Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001;7:563-568.
27. Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid model of Crohn's disease. Gastroenterology. 2003;124:961-971.
28. 1 receptor agonists. Peptides. 1997,18:1539-1545.
29. Gourlet P, Vertongen P, Vandermeers A, et al. The long-acting vasoactive intestinal polypeptide agonist Ro25-1553 is highly selective of the V1P2 receptor subclass. Peptides. 1997,18:403-408.
30. O'Donnel M, Garippa RJ, Rinaldi N, et al. Ro-25-1553: a novel, long-acting vasoactive intestinal polypeptide agonist. Part I: in vitro and in vivo bronchodilator studies. J Pharmacol Exp Ther. 1994;270:1282-1288.
31. O'Donnel M, Garippa RJ, Rinaldi N, et al. Ro-25-1553: a novel, long-acting vasoactive intestinal polypeptide agonist. Part II: effect on in vitro and in vivo models of pulmonary anaphylaxis. J Pharmacol Exp Ther. 1994;270:1289-1294.
32. Sasaki Y, Coy DH. Solid phase synthesis of peptides containing the CH2NH peptide bond isostere. Peptides. 1987;8:119-121.
33. Meldrum DR, Ayala A, Perrin MM, et al. Diltiazem restores 1L-2, IL-3, IL-6, and IFN-γ synthesis and decreases host susceptibility to sepsis following hemorrhage. J Surg Res. 1991;51:158-164.
34. Volkmann A, Zal T, Stockinger B. Antigen-presenting cells in the thymus that can negatively select MHC class II-restricted T cells recognizing a circulating self antigen. J Immunol. 1997;158:693-706.
35. LohoffM, Ferrick D, Mittrèker H-W, et al. Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity. 1997;6:681-689.
36. Toba K, Koike T, Shibata A, et al. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry. 1999;35:249-259.
37. Ceska M, Birath K, Brown B. A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Clin Chim Acta. 1969;26:437-444.
38. Zhou ZC, Gardner DG, Jensen RT. Receptors for vasoactive intestinal peptide and secretin on guinea pig pancreatic acini. Peptides. 1987;8:633-637.
39. Zhou ZC, Gardner DG, Jensen RT. Interaction of peptides related to VIP and secretin with guinea pig pancreatic acini. Am J Physiol Gastrointest Liver Physiol. 1989;256:G283-G290.
40. Jensen RT. Receptors on pancreatic acinar cells. In: Johnson LR, Jacobson ED, Christensen J, et al (eds). Physiology of the Gastrointestinal Tract, 3rd ed. New York: Raven; 1994:1377-1446.
41. Renner IG, Wisner JR. Protective effects of exogenous secretin on ceruletide-induced acute pancreatitis in the rat. J Clin Invest. 1983;72:1081-1092.
42. Segura JJ, Guerrero JM, Lopez-Gonzalez MA, et al. Vasoactive intestinal peptide (VIP) inhibits substrate adherence capacity of rat peritoneal macrophages by a mechanism that involves cAMP. Cell Adhes Commun. 1993;1:213-221.
43. Segura JJ, Guerrero JM, Pozo D, et al. Expression of vasoactive intestinal peptide binding sites in rat peritoneal macrophages is stimulated by inflammatory stimulus. J Neuroimmnol. 1994;64:1-7.
44. Delgado M, Pozo D, Martinez C, et al. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul Pept. 1996;62:161-166.
45. Pozo D, Delgado M, Martinez C, et al. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochem Biophys Acta. 1997;1359:250-262.
46. Delgado M, Munoz-Elias EJ, Kan Y, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit TOFα transcriptional activation by regulating NF-κB and CREB/c-Jun. J Biol Chem. 1998;273:31427-31436.
47. Delgado M, Munoz-Elias EJ, Gomariz RP, et al. Vasoactivs intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation. J Immunol. 1999;162:4685-4696.